Patents by Inventor Michael E. Garst

Michael E. Garst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
    Patent number: 8017655
    Abstract: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 13, 2011
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Steven W. Andrews, Robert M. Burk, Michael E. Garst
  • Naphthylmethylimidizoles as therapeutic agents
    Patent number: 8013169
    Abstract: Disclosed herein is a compound of the formula (a): Therapeutic methods, compositions and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: September 6, 2011
    Assignee: Allergan, Inc
    Inventors: Todd M. Heidelbaugh, Phong X. Nguyen, Ken Chow, Michael E. Garst
  • THERAPEUTIC COMPOUNDS
    Publication number: 20110178144
    Abstract: Disclosed herein is a compound having a structure compositions, methods, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: August 14, 2008
    Publication date: July 21, 2011
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smit S. Bhat, Todd M. Heidelbaugh, Daniel W. Gil, Ken Chow, Michael E. Garst
  • Imidazole-2-thiones
    Patent number: 7960423
    Abstract: Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: June 14, 2011
    Assignee: Allergan, Inc
    Inventors: Ken Chow, Todd M. Heidelbaugh, Daniel W. Gil, Michael E. Garst, Larry A. Wheeler
  • CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
    Publication number: 20110130439
    Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 2, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Robert M. Burk, Michael E. Garst
  • Synthesis of imidazole 2-thiones thiohydantoins
    Patent number: 7919630
    Abstract: The present invention provides a method of making an imidazole 2-thione which comprises the step(s) of reducing a thiohydantoin to said imidazole-2-thione.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: April 5, 2011
    Assignee: Allergan, Inc.
    Inventors: Michael E. Garst, Lloyd J. Dolby, Shervin Esfandiari, Alfred A. Avey, Jr., Vivian Rose MacKenzie, Charles David Muchmore
  • SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS
    Publication number: 20110077274
    Abstract: A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: wherein n=1-4; X is C or N; R1-R6 can be the same or different and are independently selected from the group consisting of H, C1-6 alkyl, OCH3, OH, F, Cl, Br, CH2OH, CH2N(R7)2, C(O)R8, CH2CN, CF3, wherein R7 is H or C1-6 alkyl; and R8 is C1-6 alkyl or aryl. The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.
    Type: Application
    Filed: December 13, 2010
    Publication date: March 31, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Smita S. Bhat, Ken Chow, Michael E. Garst
  • Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
    Patent number: 7906552
    Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: March 15, 2011
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Robert M. Burk, Michael E. Garst
  • Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
    Patent number: 7902247
    Abstract: A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: wherein n=1-4; X is C or N; R1-R6 can be the same or different and are independently selected from the group consisting of H, C1-6 alkyl, OCH3, OH, F, Cl, Br, CH2OH, CH2N(R7)2, C(O)R8, CH2CN, CF3; wherein R7 is H or C1-6 alkyl; and R8 is C1-6 alkyl or aryl. The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: March 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Todd M. Heidelbaugh, Smita S. Bhat, Ken Chow, Michael E. Garst
  • THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES
    Publication number: 20110046177
    Abstract: Disclosed herein is a stable compound having a structure formula (I): therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: August 21, 2008
    Publication date: February 24, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, Hiaqing Yuan, John E. Donello, Michael E. Garst
  • SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS
    Publication number: 20110039866
    Abstract: Described herein are compounds useful as antagonists of sphingosine-1-phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate-3 (S1P3) receptor modulation.
    Type: Application
    Filed: August 9, 2010
    Publication date: February 17, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Phong X. Nguyen, Todd M. Heidelbaugh, Ken Chow, Michael E. Garst
  • THERAPEUTIC COMPOUNDS
    Publication number: 20110039864
    Abstract: Disclosed herein is an alpha-adrenergic compound having a structure. Therapeutic methods, compositions, and medicaments for treating pain are also disclosed herein.
    Type: Application
    Filed: August 14, 2008
    Publication date: February 17, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Todd M. Heidelbaugh, Daniel W. Gil, Ken Chow, Michael E. Garst
  • Therapeutic fluoroethylcyano guanidines
    Patent number: 7884244
    Abstract: Disclosed herein is compound having a formula as described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: February 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Wenkui K. Fang, Evelyn G. Corpuz, Daniel W. Gil, Michael E. Garst
  • SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS
    Publication number: 20110028559
    Abstract: Treating pain in mammals with a compound having the formula (I) is disclosed herein.
    Type: Application
    Filed: June 20, 2008
    Publication date: February 3, 2011
    Inventors: Wenkui k. Fang, Ken Chow, Daniel W. Gil, Evelyn G. Corpuz, Michael E. Garst
  • Selective Alpha 2B/2C Agonists
    Publication number: 20110028523
    Abstract: Described herein are compounds useful as agonists of alpha 2B/2C receptors. Pharmaceutical compositions including the presently described compounds and methods of treatment of diseases and conditions with the presently described compounds also are disclosed.
    Type: Application
    Filed: July 1, 2010
    Publication date: February 3, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Wenkui K. Fang, Santosh C. Sinha, Michael E. Garst, Daniel W. Gil
  • Process for the synthesis of imidazoles
    Patent number: 7880017
    Abstract: The present invention provides a process for the preparation of imidazoles by reacting a cyano compound with a silylalkylisocyanide compound. Such imidazoles are useful pharmacologically-active compounds and/or intermediates for the preparation of pharmacologically-active compounds.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: February 1, 2011
    Assignee: Allergan, Inc.
    Inventors: Lloyd J. Dolby, Shervin Esfandiari, Michael E. Garst
  • Quinolynylmethylimidizoles as therapeutic agents
    Patent number: 7868020
    Abstract: Disclosed herein is a compound of the formula (I):(I). Therapeutic methods, compositions and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: January 11, 2011
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, Phong X. Nguyen, Ken Chow, Michael E. Garst
  • Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
    Patent number: 7863319
    Abstract: A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed. Also disclosed herein are compounds comprising or derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein. Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: January 4, 2011
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Robert M. Burk, Michael E. Garst
  • Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
    Publication number: 20100317689
    Abstract: The compounds of formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R4 group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R4 group have improved aqueous solubility, stability in plasma and improved bioavailability.
    Type: Application
    Filed: September 15, 2007
    Publication date: December 16, 2010
    Inventors: Michael E. Garst, George Sachs, Jai Moo Shin
  • CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS
    Publication number: 20100305037
    Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
    Type: Application
    Filed: May 21, 2010
    Publication date: December 2, 2010
    Applicant: ALLERGAN, INC.
    Inventors: Michael E. Garst, Michael E. Stern